Modified Factor VIII and Factor IX recombinant products

Modified Factor VIII and Factor IX recombinant products

Bibliographic Details
Main Authors:	Elena Santagostino, Maria Elisa Mancuso
Format:	Article
Language:	English
Published:	Wiley 2018-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000127

Similar Items

Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement
by: Elena Santagostino, et al.
Published: (2019-08-01)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
by: Saima Bashar, et al.
Published: (2023-04-01)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
by: Pratima Chowdary, et al.
Published: (2022-07-01)

Mathematical modeling identifies clotting factor combinations that modify thrombin generation in normal and factor VIII-, IX-, or XI-deficient blood
by: Michael T. Stobb, et al.
Published: (2024-10-01)

Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France
by: Hervé Chambost, et al.
Published: (2025-01-01)

Maturation of coagulation factor IX during Xase formation as deduced using factor VIII‐derived peptides
by: Han Fang, et al.
Published: (2019-08-01)

Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A
by: Arne W.J.H. Dielis, et al.
Published: (2008-09-01)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
by: Cecilia Augustsson, et al.
Published: (2020-10-01)

Edicija "Planiranje porodice" – knjiga VIII i IX
by: Ana Gavrilović
Published: (2005-04-01)

PB2655: EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR
by: Derya Koyun, et al.
Published: (2023-08-01)

Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision
by: Başak Koç, et al.
Published: (2020-02-01)

Matrix effect on the determination of Potency in Recombinant Coagulation Factor Ⅷ for injection
by: Jialin CHU, et al.
Published: (2022-12-01)

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
by: Mark T. Reding, et al.
Published: (2024-08-01)

Soluble expression of recombinant coagulation factor IX protein using Escherichia coli
by: Byoung-Hee Park, et al.
Published: (2024-07-01)

Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16+ NK cell activation
by: H.A. Daniel Lagassé, et al.
Published: (2024-04-01)

Lacerations to Zones VIII and IX: It Is Not Just a Tendon Injury
by: Charla R. Fischer, et al.
Published: (2011-01-01)

Gli atti arcivescovili milanesi dei secoli VIII-IX
by: Luisa Federica Zagni
Published: (2018-02-01)

A new recombinant factor VIII: from genetics to clinical use
by: Kannicht C, et al.
Published: (2015-07-01)

THE GLOBAL NEED AND AVAILABILITY OF PLASMA COAGULATION FACTORS VIII AND IX IN HEMOPHILIA CONTEXT: A GLOBAL HEALTH ESTIMATE REPORTING
by: ECDS Anjos, et al.
Published: (2023-10-01)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
by: Andreas Tiede, et al.
Published: (2020-04-01)

Henry VIII and Henry IX: unlived lives and re-written histories
by: Wright, LJ
Published: (2021)

Development of continuous cultivation of CHO cells producing recombinant blood coagulation factor VIII
by: A. N. Morozov, et al.
Published: (2018-02-01)

Single-chain recombinant clotting factor VIII (lonoctocog alfa): clinical experience in Russia
by: M. V. Kosinova
Published: (2022-02-01)

Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
by: Richard Lemons, et al.
Published: (2024-01-01)

„Włocławski” fragment karolińskiego lekcjonarza z przełomu VIII i IX wieku
by: Marcin Starzyński
Published: (2023-03-01)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
by: Jesse D. Lai, et al.
Published: (2018-11-01)

Hemostatic potential of recombinant von Willebrand factor and standard or pegylated extended half-life recombinant factor VIII on thrombus formation under high shear flow
by: Hiroaki Yaoi, et al.
Published: (2023-12-01)

Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow
by: Frauke Swieringa, et al.
Published: (2015-06-01)

Apparent factor IX inhibitor.
by: Jameela, S, et al.
Published: (2011)

Expression and Synthesis of Recombinant Human Coagulation Factor VIII Using a Cell-Free Expression System
by: M Ebrahimi, et al.
Published: (2024-03-01)

Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement
by: Margareth Castro Ozelo, et al.
Published: (2024-01-01)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
by: Yesim Dargaud, et al.
Published: (2021-12-01)

Recombinant porcine factor VIII in acquired hemophilia A: Experience from two patients and literature review
by: Alexander Hayden, et al.
Published: (2022-02-01)

Diržių kapinynas žiemgalių kultūros kontekste ir unikalūs VIII-IX a. radiniai
by: Ėrika Striškienė
Published: (2007-12-01)

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial).
by: Curry, N, et al.
Published: (2019)

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity
by: Johannes Oldenburg, et al.
Published: (2015-02-01)

Repression of factor VIII inhibitor development with apoptotic factor VIII-expressing embryonic stem cells
by: Yoshihiko Sakurai, et al.
Published: (2013-07-01)

Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph
by: Dougald M. Monroe, et al.
Published: (2016-01-01)

Factor IX and deep vein thrombosis
by: Gordon Lowe
Published: (2009-05-01)

Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
by: Thomas J. Humphries, et al.
Published: (2015-01-01)